Cite
APA Citation
Hong, D., Shergill, A., Bazhenova, L., Cho, B., Heist, R., Moreno, V., Falchook, G., Nagasaka, M., Cassier, P., Besse, B., Kim, D., Yoon, S., Le, X., Zhao, T., Atwal, S., Park, E., & Lee, J. (n.d.). preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial. European journal of cancer, 174, S72–. http://access.bl.uk/ark:/81055/vdc_100168600455.0x000045